PUBLISHER: Mordor Intelligence | PRODUCT CODE: 2063516
PUBLISHER: Mordor Intelligence | PRODUCT CODE: 2063516
According to Mordor Intelligence, the synthetic absorbable sutures market size is projected to be USD 3.06 billion in 2025, USD 3.33 billion in 2026, and reach USD 5.30 billion by 2031, growing at a CAGR of 9.75% from 2026 to 2031.

This report is Segmented by Material (Polyglactin 910, Polyglycolic Acid, Poliglecaprone 25, and More), Application (General Surgery, Orthopedic Surgery, Cardiovascular & Thoracic Surgery, Gynecology & Obstetrics, and More), End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics), and Geography (North America, and More). The Market Forecasts are Provided in Terms of Value (USD).
Procedure counts climb as populations age and chronic disease prevalence rises. Italy performed 122,777 elective total hip arthroplasties in 2023, up 80% since 2001, and models predict a further 20% rise by 2050. India's healthcare market reached USD 638 billion in 2025, and private systems plan 34,000 new beds by FY2029, supporting more elective surgeries. Growing diabetic and cardiovascular patient pools heighten demand for absorbable closure products with controlled degradation.
Robotic and laparoscopic approaches now require monofilament or barbed sutures, reducing the number of knot-tying steps. A U.S. review of 224,307 robotic cases showed that the use of knotless devices tripled in colorectal surgery and cut operating-room time by up to 19.1 minutes, without increased complications. Ambulatory surgical centers leverage these efficiencies and benefit from reimbursement parity that drives more same-day procedures.
Fibrin glues could reach USD 934.68 million by 2029 and cut OR time in hernia repair, eye surgery and vascular work. Staplers speed thoracic procedures, while ultrasonic sealers remove the need for ligatures. Sutures keep their edge where tension distribution or slow absorption is vital, and vendors now bundle sutures with hemostatics to defend share.
Other drivers and restraints analyzed in the detailed report include:
For complete list of drivers and restraints, kindly check the Table Of Contents.
Polyglactin 910 accounted for 34.58% of 2025 revenue in the synthetic absorbable sutures market. The material's braided structure assures knot security, but its surface harbors bacteria. Surgeons are now pivoting toward monofilaments such as Poliglecaprone 25, forecast to grow at a 10.54% CAGR. This shift underpins the long-term expansion of the synthetic absorbable sutures market size among minimally invasive closures. Polydioxanone retains a premium niche in orthopedic and cardiovascular work because its 180-day retention profile supports tissue remodeling.
Innovation centers on antimicrobial layering and barbed geometry: Meril's 2024 New Edge Sutures fuse silicon multi-coating with a patented point to lessen tissue drag. Research into chlorhexidine-impregnated glycomer 631 threads signals next-wave differentiation.
North America accounted for 46.46% of 2025 revenue, with the United States relying on antibacterial and barbed products to mitigate infection penalties under value-based purchasing . EPA's 90% ethylene oxide cut widens interest in hydrogen peroxide sterilization, yet may raise costs in the near term.
Europe shows mature procedure volumes; centralized tenders squeeze prices, but MDR barriers shelter established brands. B. Braun's Aesculap unit posted EUR 2.16 billion (USD 2.54 billion) in revenue and is pushing barbed Symmcora lines alongside biosurgicals. Asia-Pacific is the fastest-growing region at a 10.01% CAGR. India's med-tech push and Healthium's new plant in Sri City illustrate OEM capacity gains and export ambitions. Chinese tender systems favor domestic labels, while Japan and Australia retain premium barbed uptake. The Middle East & Africa and South America contribute smaller shares, but pockets such as GCC cesarean demand and Brazilian obstetrics sustain volume where currency swings permit.